- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.09. | Inhibrx, Eikon rise after insider buying | 2 | Seeking Alpha | ||
| 03.09. | Eikon Therapeutics, Inc.: Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer | 274 | GlobeNewswire (Europe) | MILLBRAE, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines... ► Artikel lesen | |
| EIKON THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 21.08. | Cantor Fitzgerald reiterates Overweight on Eikon stock | 1 | Investing.com | ||
| 18.08. | Eikon Therapeutics, Inc.: Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald | 2 | GlobeNewswire (USA) | ||
| 13.08. | Eikon Therapeutics, Inc. GAAP EPS of -$1.63 misses by $0.03 | 1 | Seeking Alpha | ||
| 13.08. | Eikon Therapeutics, Inc.: Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates | 285 | GlobeNewswire (Europe) | Eikon announced seven abstracts accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026 highlighting progress across Eikon's oncology portfolio, including clinical... ► Artikel lesen | |
| 13.08. | Eikon Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 11.08. | Eikon Therapeutics, Inc.: Eikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced Melanoma | 514 | GlobeNewswire (Europe) | Selected 0.60 mg/m2 as the single dose for the TeLuRide-006 study going forward for patients randomized to EIK1001 treatment, in accord with a recommendation of the independent Data Monitoring Committee... ► Artikel lesen | |
| 10.08. | Eikon Therapeutics adds Merck chemistry head to advisory board | 3 | Investing.com | ||
| 10.08. | Merck Chemiechef verstärkt wissenschaftlichen Beirat von Eikon Therapeutics | 4 | Investing.com Deutsch | ||
| 10.08. | Eikon Therapeutics, Inc.: Eikon Therapeutics Appoints Johnny Bennett, Ph.D. to its Scientific Advisory Board | 439 | GlobeNewswire (Europe) | MILLBRAE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines... ► Artikel lesen | |
| 03.08. | Eikon Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.07. | Eikon Therapeutics doses first patient in lung cancer trial | 1 | Investing.com | ||
| 27.07. | Eikon Therapeutics, Inc.: Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer | 213 | GlobeNewswire (Europe) | MILLBRAE, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to... ► Artikel lesen | |
| 20.07. | Eikon Therapeutics, Inc.: Eikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) Congress | 1 | GlobeNewswire (USA) | ||
| 25.06. | Eikon Therapeutics to join Russell 3000 index | 1 | Seeking Alpha | ||
| 25.06. | Eikon Therapeutics, Inc.: Eikon Therapeutics to Join the Russell 3000 Index | 175 | GlobeNewswire (Europe) | MILLBRAE, Calif., June 25, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines... ► Artikel lesen | |
| 10.06. | Eikon Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.06. | Eikon Therapeutics beruft Ma. Fatima Francisco in den Verwaltungsrat | 2 | Investing.com Deutsch | ||
| 08.06. | Eikon Therapeutics appoints Francisco to board of directors | 1 | Investing.com |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVAVAX | 11,300 | -0,70 % | Novavax-Aktie +20%: Woher kommt plötzlich die Fantasie? | Die Novavax-Aktie schoss zum Wochenauftakt um +20% in die Höhe und ging am Montagabend fast auf einem neuen 2-Jahreshoch aus dem Handel. Was steckt hinter dem Kurssprung des Impfstoffherstellers und... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,024 | +0,10 % | INOVIO PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| INFLARX | 1,468 | +3,09 % | BRANDMELDUNG bei InflaRx NV: Meine brandneue Prognose ändert einfach alles - Handeln Sie noch vor dem Wochenende! | ||
| INTELLIA THERAPEUTICS | 11,800 | +1,03 % | Intellia Therapeutics-Aktie: Sind 80 US$ möglich? | Die Intellia-Therapeutics-Aktie notiert aktuell bei 12,37 US$ und damit mehr als -90% unter ihrem bisherigen Rekordhoch. Nach dem Ausbruch aus dem langjährigen Abwärtstrend versucht der Biotech-Titel... ► Artikel lesen | |
| EDITAS MEDICINE | 2,590 | 0,00 % | Editas Medicine, Inc.: Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia | Phase 1/2 clinical trial of EDIT-401 cleared to initiate dosing in patients who require additional LDL-C lowering Company remains on track to begin patient dosing this year and report initial safety... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,363 | -5,47 % | 7 Jahre USA, 10 Jahre EU: Warum Biogen, Novartis und NurExone auf den Orphan-Drug-Pfad setzen | ||
| IBIO | 0,839 | +6,95 % | iBio, Inc.: iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update | SAN DIEGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary... ► Artikel lesen | |
| GERON | 1,075 | 0,00 % | Geron-Aktie mit -98% - große Chance oder großes Risiko? | Die Geron-Aktie notiert aktuell bei 1,21 US$ und befindet sich erneut an einer langfristig wichtigen Unterstützungszone. Seit dem Zwischenhoch von 2024 hat der Biotech-Titel rund drei Viertel seines... ► Artikel lesen | |
| IMMUNITYBIO | 9,400 | +0,21 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| IMMATICS | 6,605 | 0,00 % | Immatics Announces $150 Million Underwritten Offering | Houston, Texas and Tuebingen, Germany, August 25, 2026 - Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), the global leader in precision targeting of PRAME with multiple clinical-stage programs... ► Artikel lesen | |
| MYRIAD GENETICS | 3,844 | 0,00 % | Myriad Genetics, Inc.: Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology | SALT LAKE CITY and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine and SOPHiA GENETICS (NASDAQ: SOPH)... ► Artikel lesen | |
| MANNKIND | 2,925 | -0,58 % | MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow' for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD) | ||
| GINKGO BIOWORKS | 11,610 | -0,04 % | What's Going on With Ginkgo Bioworks Stock on Friday? | ||
| IMMUNIC | 7,368 | +0,63 % | EQS-News: Immunic AG: Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 13,020 | -0,15 % | Transcript: Iovance Biotherapeutics Q2 2026 Earnings Conference Call |
Das Unternehmen EIKON THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,005 (-0,07 %) liegt der Kurs bei 7,465 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EIKON THERAPEUTICS INC finden Sie auf Wallstreet Online.